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Abstract 
Introduction: Health economics models are typically built in Microsoft Excel® owing to its wide 
familiarity, accessibility and perceived transparency. However, given the increasingly rapid and 
analytically complex decision-making needs of both the pharmaceutical industry and the field of 
health economics and outcomes research (HEOR), the demands of cost-effectiveness analyses may be 
better met by the programming language R. 
Objective: This case study provides an explicit comparison between Excel and R for contemporary 
cost-effectiveness analysis. 
Methods: We constructed duplicate cost-effectiveness models using Excel and R (with a user 
interface built using the Shiny package) to address a hypothetical case study typical of contemporary 
health technology assessment.  
Results: We compared R and Excel versions of the same model design to determine the advantages 
and limitations of the modelling platforms in terms of (i) analytical capability, (ii) data safety, (iii) 
building considerations, (iv) usability for technical and non-technical users and (v) model 
adaptability. 
Conclusions: The findings of this explicit comparison are used to produce recommendations for when 
R might be more suitable than Excel in contemporary cost-effectiveness analyses. We conclude that 
selection of appropriate modelling software needs to consider case-by-case modelling requirements, 
particularly (i) intended audience, (ii) complexity of analysis, (iii) nature and frequency of updates 
and (iv) anticipated model run-time.  
 
 




• We present duplicate health economics models for a hypothetical chimeric antigen receptor 
treatment, built in Excel and R with an interface using the Shiny package 
• We provide an explicit comparison between the two software platforms for contemporary 
cost-effectiveness analysis 
• We discuss when R might be preferable to Excel in contemporary cost-effectiveness analysis 





1.1. R as an alternative to Excel for cost-effectiveness modelling 
Since health technology assessment (HTA)-informed decision-making came to prominence in the late 
20th century, the software of choice for health economic models has been Microsoft Excel®. This is 
understandable, Microsoft Office® has been almost as ubiquitous as the desktop computer since the 
1990s. For cohort-level models, Excel’s spreadsheet interface is typically sufficient to calculate 
deterministic results in near-real time. The low cost and fluency benefits of Excel in this context are 
not limited to the model builder. A model built in Excel is more accessible to reviewers, managers, 
clinicians and patients than one presented in code. For an alternative platform to be preferential to 
Excel in a health economic modelling application, its relative build and execution advantages should 
be considered alongside accessibility, fluency and transparency.  
R has been available as open-source software since 2000 [1, 2], and the use of R for health economic 
modelling is not new. Examples of note include the cost-effectiveness model for the 2006 HTA 
monograph for etanercept and efalizumab to treat psoriasis, the model developed by the University of 
Sheffield School of Health and Related Research for the assessment of rituximab for the first-line 
treatment of Stage III–IV follicular lymphoma in 2011, and the assessment of opioid agonists by the 
US Institute for Clinical and Economic Review [3-5]. Recently, R has been increasingly considered as 
an alternative to Excel for health economic modelling. In July 2018, University College London 
hosted its first annual event with presentations from academic and industry modellers working in 
health economic evaluation, exploring and promoting the use of R as an alternative to Excel for cost-
effectiveness analysis [6]. In addition, numerous papers have been published demonstrating the 
benefits of statistical software over Excel [7-12]. 
For health economic modelling, R holds a key advantage over Excel. With its primary function as a 
statistical software, R allows the user to consolidate and calculate in real time the underlying statistics 
informing health economic decision problems (referred to henceforth as ‘end-to-end’ functionality) – 
for example, survival analysis of patient-level registrational trial data to inform a three-state oncology 
model. End-to-end functionality is of considerable advantage as it allows both internal and external 
validity to be demonstrated all the way from input data to decision analytic endpoint, with uncertainty 
analyses and reporting all in one place. Given a comparable level of modelling experience, 
construction in R with end-to-end functionality provides superior consistency and efficiency 
compared to Excel, an argument that has been made elsewhere [12]. 
 
1.2. Comparative transparency of R versus Excel 
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The advantages of Excel over R in current HTA modelling include perception of transparency and 
audience familiarity [13-15]. Transparency can be defined as provision of documentation on a 
model’s structure, equations, parameter values and assumptions. To be fully transparent, the model 
needs to be understandable to both non-modellers and modellers who may want to replicate the model 
and findings [16, 17]. Models implemented using R are transparent in ways unfamiliar to Excel. End-
to-end functionality lends itself to more transparent HTA submissions, as functions can be tested in 
isolation, and internal and external validation throughout statistical and modelling steps can be 
incorporated into the model itself. R packages can be freely validated as they are open-source, while 
R scripts force the analyst to construct models in a linear fashion, which are arguably easier to grasp 
than often disjointed and sometimes incoherent Excel implementations. For additional transparency, 
outputs of analyses conducted in R can be embedded within pre-formatted reports via the text 
conversion tool, R Markdown, such that documents are readily reproducible and a clear trail from 
analysis to output can be followed [18]. An additional benefit of R is that code development can be 
managed in tracked stages using readily accessible version control software, allowing parallel 
workstreams with staged reviews and merges [19]. However, those same HTA stakeholders who 
likely recognize Excel spreadsheets – reviewers, managers, clinicians and patients – are unlikely to be 
familiar with R code. In this sense, an Excel-based health economic model has clear transparency 
advantages over a similar model in R. In late 2019, this translates as a hard barrier for R for global 
HTA cost-effectiveness models: some key HTA bodies do not accept models in R, including the 
Dutch National Health Care Institute, Zorginstituut Nederland [20-22]. For multinational 
pharmaceutical companies developing submissions to HTA bodies globally, this can understandably 
be enough to preclude R as a choice for late-stage cost-effectiveness modelling. However, R is 
becoming more familiar, and HTA bodies are increasingly moving to accept cost-effectiveness 
models in R [23]. 
 
1.3. Incorporation of Shiny within R models to improve user-accessibility and produce 
applications for online distribution 
Shiny is a package for R that allows construction of an interactive graphical user-interface associated 
with the accompanying R code [24]. Shiny is increasingly being used by health economic modellers 
[25]. A model built with Shiny comprises two parts: a user-interface and a server. The user-interface 
is designed to be user-friendly; the server operates as the engine. Shiny allows the user to amend 
inputs in a similar manner to Excel without needing to access the background R code. In this sense, an 
R model using Shiny is comparable to an Excel model developed in part within Visual Basic for 
Applications® (VBA) code, but with capability for complex statistical analysis, model flexibility and 
high-quality visuals. Several Shiny-based health economic models have been disseminated to date, 
including two open-source value tools from the Innovation and Value Initiative (IVI) [26]. 
Additionally, initiatives such as those undertaken by the US Food and Drug Administration (FDA) 
tool for searching drug safety reporting ratios, the Personalized Medicine Economics Research tool 
developed by the University of Washington, and the Global health cost-effectiveness analysis registry 
produced by the Center for the Evaluation of Value and Risk demonstrate the application and 
relevance of Shiny from a broader HTA perspective [27-29].  
Of course, a Shiny interface is not sufficient for a reviewer to understand the underlying mechanisms 
of a model. However, its use serves as a bridge between complex functionality and model 
accessibility and may make R more appealing to health economic audiences. 
 
1.4. The increasing need for analytical complexity to estimate long-term treatment 
effectiveness: a case study for our times 
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The benefit of R over Excel as a platform for both statistical analysis (e.g. survival analysis) of 
patient-level data (PLD) and cost-effectiveness modelling is becoming increasingly important, owing 
to changes in the development, delivery and funding of medicines. For technologies addressing high 
unmet need, the European Medicines Agency (EMA) and the FDA have lowered the evidence 
generation hurdle, allowing interventions to receive accelerated approval based on single-arm Phase II 
study data with limited follow-up [30-32]. Between 1 January 1999 and 8 May 2014, 76 unique 
licences were granted by the EMA and FDA in the absence of randomized controlled trial data [33]. 
Consequently, a far greater scope of statistical analysis is required to appropriately reflect the 
uncertainty in the expected treatment benefit estimates from such limited data.  
In 2018, the first EMA and FDA chimeric antigen receptor (CAR) T-cell therapy licences were 
granted for use of tisagenlecleucel and axicabtagene ciloleucel in haematological malignancies [34-
37]. When assessing the cost effectiveness of a CAR T-cell therapy at time of regulatory approval, 
characteristic issues include (i) potential benefits that far exceed the relatively short duration of trial 
follow up, and (ii) a lack of randomized evidence versus the comparator [38]. Owing to the novelty of 
CAR T-cell therapy, combined with the complexity of statistical analyses required to adequately 
assess cost and survival outcomes, this technology was selected as the intervention in our hypothetical 
case study as an exemplar of a contemporary problem of our time [39, 40]. This case study was used 
to produce an explicit comparison between Excel and R with Shiny interface in cost-effectiveness 
analysis. We have chosen a hypothetical case study using simulated data because the objective of this 
paper is to compare modelling platforms, rather than deriving a cost-effectiveness ‘answer’, and 
because the authors do not own PLD from regulatory trials. The decision problem presented here uses 
a simulated paediatric B-cell acute lymphoblastic leukaemia patient dataset, mimicking typical data 
limitations of the indication as described in Hettle et al. [38], to model the intervention’s incremental 
benefit versus chemotherapy. 
 
1.5. Aims  
Our primary aim is to present novel, illustrative evidence on the relative appropriateness of R versus 
Excel for contemporary cost-effectiveness modelling. A secondary aim is to add to the growing 
demonstrative evidence that provision of a graphical user-interface (such as Shiny) can improve R 
model accessibility. To this end, we built equivalent cost-effectiveness models in both R with Shiny 




2.1. Model software and access 
A model was constructed in R with Shiny and is referred to here as the intRface™ model (Interactive 
R: Flexible Applications for Cost-effectiveness – available to view via the following the link: 
intRface). The purpose of the subsequent Excel model build was twofold: (i) for validation and (ii) for 
comparison. The Excel model is available to view in Online Resource 1. Both models used the same 
base case inputs and produced the same base case results, fulfilled the objective of addressing the 
decision problem and adhered to the National Institute for Health and Care Excellence (NICE) 
Decision Support Unit (DSU) modelling guidelines. The methods, assumptions and measured 
outcomes of the models are summarized in Online Resource 2. 
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2.2. Cost-effectiveness model structure 
The hypothetical case study was approached from a UK perspective, using guidelines from the NICE 
DSU Technical Support Documents (TSDs). Broadly in line with the 2018 NICE single technology 
appraisals (STAs) of tisagenlecleucel and axicabtagene ciloleucel within their licensed indications 
[41-43], we used a cohort-level cost-effectiveness model, structured with three health states: 
progression-free (PF), post-progression (PP) and death. The methods described in the NICE DSU 
TSD 19 to determine cohort health state membership over time were used to include both state-
transition modelling (StateTM) and partitioned survival analysis (PartSA) structures. This was owing 
to the recommendation that where PartSA is used, StateTM should also be used to assist in verifying 
the plausibility of extrapolations and to address uncertainties in the extrapolation period [44]. 
The model objective was to capture and summarize lifetime patient health outcomes and UK National 
Health Service costs. To measure this, an 80-year time horizon and a 28-day cycle length were used 
with a 3.5% annual discount rate for costs and quality-adjusted life years [45]. Fig. 1 summarizes the 
model structure and analysis steps taken to capture cost-effectiveness outcomes for the decision 
problem.  
 
Fig. 1: Schematic of objectives for cost-effectiveness model end-to-end functionality 
 
CAR, chimeric antigen receptor; DSU, Decision Support Unit; NICE, National Institute for Health 
and Care Excellence; PartSA, partitioned survival analysis; PLD, patient-level data; StateTM, state-
transition modelling; TSD, technical support document. 
 
2.3. Analysis requirements 
The technical complexities of the decision problem were considered when simulating the PLD and 
scoping the analysis requirements. PLD were simulated for CAR T-cell therapy and clofarabine as 
two single-arm trials, each with two data-cuts. A simulated 24-month data-cut was used as the base 
case for all analyses, with the option to switch to a 36-month data-cut to demonstrate the inclusion of 
an ‘updated data-cut’. Prognostic patient characteristics as reported by studies in paediatric B-cell 
acute lymphoblastic leukaemia [46, 47] were used alongside available Kaplan–Meier (KM) data 
reported by Hettle et al. and in the axicabtagene ciloleucel NICE STA [48, 38] to simulate PLD, 
consisting of patient characteristics as well as censoring and event data for progression-free survival 
(PFS) and overall survival (OS).  
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Matching analysis functionality was included in the model as the simulated single-arm trials 
necessitated that an analysis be included to account for the lack of randomization and potential for 
bias of treatment effect. NICE DSU TSD 17 guidance [49] outlines several methods to address the 
problems presented by non-randomized data. Based on assumptions that the simulated data observed 
all factors that influence relevant patient outcomes, and that there was sufficient overlap of similar 
patients between the two trials, propensity score matching analysis was included. Matching aims to 
mimic trial randomization, creating a subset of the data by selecting patients from the treated and 
control groups who are similar to each other in baseline characteristics [50, 51]. 
To extrapolate health outcomes over the time horizon, NICE DSU TSD 14 guidance [52] was 
consulted to determine the parametric survival models used for analysing the time-to-event data. In 
line with this guidance, functionality was included that recommends suitable outcomes for assessing 
the validity of distributions, including visual inspection of the extrapolations versus the KM and 
providing the Akaike information criterion and Bayesian information criterion statistics. Parametric 
model outcomes were then used to determine health state membership over time for both StateTM and 
PartSA.  
Different patient groups may be expected to experience different survival rates depending on their 
response to immunotherapies, and it has been reported that CAR T-cell therapy has the potential to 
induce long-term remission [41-43]. A frequent limitation of emerging therapies is that patient follow-
up is insufficient and traditional parametric extrapolations of survival may not be representative of 
real-world patient outcomes. “Mixture-cure” functionality was therefore included as a modelling 
option to allow the production of outcomes where a proportion of the patient population is ‘cured’ and 
therefore experiences a probability of death equal to that of the calculated age-matched general 
population estimates [53, 54]. The ‘cured’ and ‘uncured’ patient populations are then combined to 
produce curves for the overall population [55, 56]. 
 
3. Results 
An explicit comparison between the constructed intRface and Excel models was undertaken to 
consider key issues often encountered within health economic modelling surrounding transparency, 
build and adaptation efficiency, or analytical limitations: (i) analytical capability, (ii) data safety, (iii) 
model building, (iv) usability for technical and non-technical users and (v) model adaptability. We use 
this comparison to recommend scoping considerations required to inform the suitability of R for cost-
effectiveness modelling on a case-by-case basis. 
 
3.1. Comparative model capability 
The analytical capabilities of R are such that a model built using this platform can include all the 
required stages of analysis from using the PLD to reporting outcomes, giving models end-to-end 
functionality. This is not possible in Excel because of the more limited analysis capabilities. Some 
inputs for the Excel model needed to be derived outside of Excel, such as the propensity score 
matching results and parametric survival curve parameters. In this case study, they were extracted 
from the R model. The analytical capabilities of each model are presented in Table 1. 
 
Table 1: Comparative analytical capabilities between intRface and Excel models  
Functionality intRface model Excel model 
Live propensity score Included with the ability to add or Not possible to include: only 
R and Shiny for cost-effectiveness analyses: why and when? A hypothetical case study  
7 
 
Functionality intRface model Excel model 
matching analysis remove existing covariates from 
the analysis. The unmatched data 
can also be used if propensity 
score matching is not required 
scenarios that have been previously 
run can be explored. Matching 
analysis needs to be run externally, 
and results copied into model 
Live fitting of 
parametric models 
All parametric models are fitted to 
the active dataset  
Parametric models need to be fitted 
to the active dataset externally, and 
results copied into model – a 
laborious task for updates to data-
cut or subgroup exploration 
PartSA (including 
MCM) and StateTM 
modelling 
Model includes PartSA and 
StateTM modelling strategies. 
These are informed by the 
internally calculated parametric 
fits 
Model includes PartSA and 
StateTM modelling strategies. 
These are informed by models fit 
outside of Excel with estimates 
pasted in 
Probabilistic sensitivity 
analysis – time taken for 
1,000 PSA runs using 
base case settings 
1.42 minutes 13.2 minutes 
One-way sensitivity 
analysis – time taken to 
run 109 parameter 
scenarios 
0.27 minutes 2.4 minutes 
Automatic report 
generation 
Report template is set up within 
RMD to automatically populate 
tables and figures with active 
modelling analyses when selected 
Highly challenging to include; not 
included 
Quality control • Table included with selected 
diagnostic checks 
• Linear code with vectors and 
data frames produced by 
single calculations that need 
to be checked once. 
However, tracing an 
individual calculation from 
start to finish can take longer 
than in Excel 
• Packages used are open-
source: version to be used 
needs to be defined to ensure 
stability over time 
• Diagnostic checks included in 
patient flow sheet 
• Cell-by-cell checks were 
required across all sheets 
because of individual 
calculations, meaning there 
was potential for drag down 
error and inconsistency 
within columns and data 
frames 
Model size 5.1 MB – Includes R scripts and 
Excel input workbooks containing 
simulated PLD, general 
population survival statistics and 
cost inputs 
30.9 MB – Single workbook  
Version control Managed by the version control 
software Git to allow tracked 
changes, code reversions and 
parallel work streams 
Manual change log. Multiple 
versions required to allow 
reversions. Difficult to work in 
parallel 
Key: MB, megabytes; MCM, mixture-cure modelling; PartSA, partitioned survival analysis; PLD, 
patient-level data; RMD, R Markdown; StateTM, state transition model. 
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3.2. Data safety 
The incorporation of externally derived values into cost-effectiveness models is widely practised to 
preserve the confidentiality of trial data; however, this is not possible for a model with end-to-end 
functionality. Where PLD are incorporated within end-to-end models, they can be used both locally 
and online via hosting software and secure servers with user authentication [57]. However, in stages 
of model development where external distribution and validation are required, it is understood that 
having any PLD contained within the model may breach data security. As within Excel, in R it is 
possible to remove the PLD from a model and save the results and statistics of analyses requiring PLD 
for later use in cost-effectiveness analysis. This delinking from PLD dependency should be done at 
the last moment prior to external dissemination to allow full functionality to be maintained as long as 
required.  
 
3.3. Model building 
Developing the intRface model presented coding challenges that were not required in producing the 
Excel model, owing to the differences in the included functionality. Consequently, the intRface model 
build took significantly longer than the Excel model. However, the Excel model was dependent on the 
matching analysis and survival extrapolation analysis from R. This would remain so even if the full 
intRface model was not constructed, and there would still be the need to revisit R to obtain new 
estimates upon any change in data. It should also be acknowledged that the flow of information within 
an R model wrapped in Shiny functionality is not as linear as a model produced in R alone, which 
adds additional coding complexity. It is for these reasons that when considering the platform for 
model build, functionality requirements should be considered alongside potential model building 
challenges, requirements for review and audience familiarity, and subsequent adaptability to ensure 
overall project efficiency.  
 
3.4. Comparative usability 
The usability of a cost-effectiveness model in R is dependent on the user’s familiarity with R 
language. In this application, the Shiny package was used to create a user-interface to allow multi-
stakeholder user interaction with underlying R functionality without being exposed to the script. This 
combination of user-friendly interactivity with powerful R functionality ensures that users can view 
and amend complex analyses where previously there was little accessibility. The propensity score 
matching analysis within intRface is a good example of this, where users can select covariates, 
instantaneously view the results of the matching analysis and incorporate these into cost-effectiveness 
calculations. Whilst useful, such accessibility should be treated with caution to ensure that the 
functionality options available cannot be abused by users to push unfounded or biased assumptions. 
Consideration of audience knowledge, statistical validation and anticipated adaptability requirements 
should be balanced in informing available options.  
Both the Excel and intRface model presented value input tables and dropdown options in clear model 
‘pages’. The only significant difference to user experience from this perspective is the model 
reactivity. The Excel model reactivity is such that amending values automatically updates the model. 
Within intRface, updating and running the model is triggered by buttons. Because of the ready 
availability of ‘update’ buttons within intRface, this was not found to be detrimental to user-
experience. An advantage of R that has been included within intRface is the ability to produce 
interactive graphics that are responsive to hovering and convenient graph display options that inform 
users of relevant amendable options (Fig. 2). 




Fig. 2: User-interactive outcome display options available within interface 
 
A) Survival analysis graph display with hover functionality, user-amendable axis slider, curve 
selection options and AIC/BIC tables within ‘Efficacy analysis: Select curves’ page; B) Propensity 
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score matching results graph, display options, and table presenting hazard ratios for matched and 
unmatched datasets within ‘Survival data: Propensity score matching’ page of intRface. 
AIC, Akaike information criterion; BIC, Bayesian information criterion; CAR, chimeric antigen 
receptor; KM, Kaplan–Meier; PFS, progression-free survival. 
 
3.5. Comparative adaptability 
An essential consideration for any model is that it has the required level of flexibility to react to 
anticipated adaptation. Modelling for HTA often involves adaptation of existing models to different 
localities and amendment to include updated data. Sufficient flexibility to amend base case modelling 
options and costs and to update trial data-cuts may be required. We therefore consider the suitability 
of both models in light of common adaptation requirements. We considered hypothetical adaptation 
scenarios in Table 2. The main difference between the two models is in the derivation and use of 
statistical analysis. In the intRface model, the changes to the raw data or matching analysis 
automatically feed through to the cost-effectiveness model. However, because the Excel model is 
dependent on externally derived estimates, updating these with a new analysis or data-cut would 
involve extensive copying and pasting of all results for each of the modelling strategies, significantly 
increasing the potential for error. The intRface model limits the potential for copy-and-paste error 
because the functionality to pass analysis outputs to model inputs already exists. 
 
Table 2: Hypothetical model adaptation scenarios 
Adaptation intRface model Excel model 
Update to data cut • Ensure that the new data are in 
the same format as previous 
data file 
• Link the file containing the data 
to the correct switch option 
• Sense check to ensure data are 
feeding through 
• Ensure that the new data are in 
the same format as previous 
data file 
• Re-run to produce new results 
(accounting for propensity score 
matching if required) in R and 
then extract these covariates 
• Copy and paste covariates for 
PartSA (including MCM) and 
StateTM into the model 
• QC check required to ensure 





• Select new covariate selection, 
calliper, and data-cut 
• Select button to update analysis 
• Re-run analysis and extract new 
covariates from R 
• Copy and paste covariates for 
PartSA (including MCM) and 
StateTM into the model 
• QC check required to ensure 
correct curves are being 
produced 
Adaptation of 
inputs for local 
affiliates 
Costs: 
• Fill in costs sheet by sending 
the Excel template to affiliate 
contact 
• Link the Excel sheet to the 
country switch in the model 
Costs: 
• Fill in costs sheet by sending 
the Excel template to affiliate 
contact 
• Copy and paste values into the 
ranges required 
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Adaptation intRface model Excel model 
 
Model options: 
• Overwrite current switch values 
 
Model options: 




A report template is written in RMD 
where the figures and tables 
reference the active model settings 
and outcomes. 
A button is then selected from within 
intRface and produces a Microsoft 
Word® document with required 
figures, tables, styles, headings and 
bibliography. 
For any subsequent change in results, 
a new Word document can be 
produced with updated tables and 
figures automatically incorporated. 
Required changes to the text for 
interpretation will need to be made 
manually in Word or RMD 
A report is written in Microsoft Word 
where the figures and tables are 
copied from Excel.  
For any subsequent change in results, 
the figures and tables are re-copied 
from Excel. This increases the 
chance of error and will require a QC 
cross-check. 
Required changes to the text for 
interpretation will need to be made 
manually in Word 
New functionality 
(e.g. addition of 
new health state 
or tunnel states) 
Case-by-case consideration required. If previous R functionality exists in a 
modular format, then time and effort to incorporate functionality will most 
likely be faster in R or at worst similar between the two software options. 
This is particularly the case for implementation of tunnel states, which is not 
a short job in Excel. 
Removing 
functionality 
Case-by-case consideration required. Anticipated to be similar time and effort 
required in most instances.  
Key: MCM, mixture-cure modelling; PartSA, partitioned survival analysis; QC, quality control; 
RMD, R Markdown; StateTM, state transition model. 
 
4. Discussion 
We have provided an illustrative example of the differences in the complexity, functionality and 
adaptability of a similar cost-effectiveness model build in Excel and R. When choosing the software 
for an economic model, we advise consideration of the lifetime purpose, audience and technical 
requirements of the analysis, particularly as alternatives to Excel as a cost-effectiveness modelling 
platform become more widely accepted by HTA bodies. The hypothetical case study selected here 
presented modelling issues and analyses that are not universal across health economic decision 
problems; however, when they do arise, awareness of the relative merits of different software 
platforms for cost-effectiveness modelling may be valuable.  
In general, model developers and reviewers are likely to remain more comfortable constructing and 
reviewing models that are programmed in Excel. When an analysis can be programmed in Excel and 
remain ‘fit for purpose’ in terms of computational efficiency and analytic transparency, there seems 
little benefit in moving to an alternative approach. Moving forward, increasing acceptance by external 
reviewers will be driven by increased training as part of health economics courses and using accepted 
and validated code for as many functionalities as feasible, with new analyses being well highlighted 
and documented [58]. 
When would we anticipate that programming in R will lead to substantive improvements in efficiency 
and transparency? In which contexts are the benefits likely to outweigh the costs to programmers and 
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reviewers of working in a less familiar platform? It is anticipated that such economic evaluations will 
meet the first of the following criteria, and are likely to meet one or more of criteria 2–4:  
1. The intended audience (e.g. the company undertaking early evaluation of product potential or 
the HTA body) accepts economic evaluations in R. Furthermore, there is confidence that any 
reviewers of central importance have the capacity and inclination to review an evaluation 
undertaken in R. There is substantial heterogeneity in the willingness of different HTA bodies 
to review analyses that are more analytically demanding than cohort-based Excel models [7]. 
NICE accepts models written in R [59]; the use of R can be accepted by other HTA bodies 
but typically requires pre-approval [60-62]. 
2. A number of complex statistical analytical methods are required to generate the inputs that 
drive patient transitions within the economic model, such that there is a substantial 
transparency benefit to being able to review how these statistical analyses and the resulting 
uncertainty are undertaken and incorporated into the economic evaluation. 
3. There are likely to be late and/or multiple changes to either the underlying data informing the 
economic evaluation or the approach taken to statistically analyse these data, and these are 
likely to be required with quick turnaround.  
4. The core economic model would have a long run-time if undertaken in Excel front-end. This 
includes analyses such as patient-level simulations. However, if a simulation is coded in 
VBA, comparable reviewer-transparency issues may be faced across R and Excel, such that a 
key benefit of using Excel is lost even if the speed is similar [63]. 
Widespread adoption of R with or without a user-interface would bring benefits to the field of health 
economic modelling, namely transparent, reproducible and adaptable models that have reusable 
functionality and are more capable of quantifying decision uncertainty [7]. If the trend to undertake 
HTA in parallel to the regulatory process becomes more widespread, the third stated criterion (the 
need to update underlying data) will become increasingly relevant. If regulatory and HTA evaluations 
are undertaken earlier in the drug development process, when clinical effectiveness data are less 
mature and there is an increased reliance on complex statistical methods to estimate the ‘true’ benefit 
and uncertainty surrounding this for an intervention, the likelihood of the fourth stated criterion 
increases. Of course, if a greater number of models are constructed using R, the technical barrier to 
programmers and reviewers will continue to fall, as a result of both accumulated experience and the 
standardization of methods, functions and frameworks [15]. The capacity to readily incorporate 
standardized functions means it is not difficult to envision a future in which R-based models are 
considered easier to appraise than Excel-based models. 
In this study, we have considered R versus Excel for cost-effectiveness models with the design 
specified to HTA requirements. Earlier in the drug development process, the comparative advantages 
of R versus Excel to inform go/no-go decision-making are related to those exposed here, but worthy 
of further consideration. R may also have a growing role in model validation and quality control of 
Excel models [64]. 
R is not a silver bullet for the wider issues faced by the HTA community. The tension between 
accelerated access and a desire for robust HTA decision making will remain. At a more mundane 
level, analysts will always need to follow conventions of good practice when annotating their code 
and clearly report modelling methods, assumptions and implementation decisions. An additional 
consideration is the alteration and updating of R packages, which would require models to be 
regularly reviewed and maintained to ensure update compatibility if distributed via R and not a 
controlled server. However, by providing a user-friendly platform that allows all crucial analyses to 
be undertaken in one location, R models can serve analysts and the wider community in generating 
analyses that are more efficient, less error prone and more transparent than would be the case if 
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undertaken in Excel. It is hoped our efforts here can help others in the field make informed software 
selection decisions for HTA cost-effectiveness models, on a case-by-case basis. 
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